# THISTLE - The HIV-HCV Silibinin Trial

> **NCT01816490** · PHASE2 · COMPLETED · sponsor: **University of Zurich** · enrollment: 20 (estimated)

## Conditions studied

- HIV
- Hepatitis C

## Interventions

- **DRUG:** Intravenous Silibinin (iSIL)

## Key facts

- **NCT ID:** NCT01816490
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01816490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01816490, "THISTLE - The HIV-HCV Silibinin Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01816490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*